CRISPR Therapeutics shares climbed after rumors suggested a large U.S. biopharma company may be exploring a potential acquisition, fueled by progress in gene editing programs and growing Casgevy sales.
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.
